Calidi Biotherapeutics Inc. (CLDI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has a cash flow conversion efficiency ratio of -1.342x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.04 Million) by net assets ($3.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Calidi Biotherapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Calidi Biotherapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Calidi Biotherapeutics Inc. for a breakdown of total debt and financial obligations.
Calidi Biotherapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
-1.214x |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
-0.078x |
|
NORTHERN SHIELD RES INC.
F:N9SA
|
N/A |
|
Bathurst Metals Corp
V:BMV
|
-0.113x |
|
Olivers Real Food Ltd
AU:OLI
|
-0.053x |
|
Purple Biotech
NASDAQ:PPBT
|
-0.108x |
|
ZIMI Ltd
AU:ZMM
|
-0.423x |
|
Valion Bio Inc
NASDAQ:VBIO
|
-0.136x |
Annual Cash Flow Conversion Efficiency for Calidi Biotherapeutics Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Calidi Biotherapeutics Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Calidi Biotherapeutics Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.76 Million | $-21.29 Million | -5.665x | +43.39% |
| 2024-12-31 | $1.97 Million | $-19.69 Million | -10.007x | -405.41% |
| 2023-12-31 | $-8.23 Million | $-26.98 Million | 3.277x | +1150.74% |
| 2022-12-31 | $-50.44 Million | $-13.21 Million | 0.262x | -23.80% |
| 2021-12-31 | $-22.61 Million | $-7.77 Million | 0.344x | +60.15% |
| 2020-12-31 | $-22.48 Million | $-4.83 Million | 0.215x | -- |
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more